{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:41:28Z","timestamp":1792518088821,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-026-01499-5","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:35:14Z","timestamp":1786790114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward harmonized PROMISE PSMA scoring: a simple approach for correcting 18F-PSMA-1007 liver uptake based on 68Ga-PSMA-11 and 18F-DCFPyL reference values"],"prefix":"10.1186","volume":"16","author":[{"given":"Reut","family":"Anconina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Priss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Sason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Atar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-8994","authenticated-orcid":false,"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bernstine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-4806","authenticated-orcid":false,"given":"Dan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2967\/jnumed.117.201749","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET-CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 10 ng\/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230\u20137.","journal-title":"J Nucl Med."},{"key":"1499_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394.","journal-title":"Lancet Oncol"},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET-CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674\u201382.","journal-title":"Clin Cancer Res"},{"key":"1499_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, et al. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38:200\u201317.","journal-title":"Radiographics"},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich U, Eder M. 68Ga-Ga-PSMA-11: the first FDA-approved Ga-68-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14:713.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1499_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nucmedbio.2021.12.005","volume":"106","author":"S Piron","year":"2022","unstructured":"Piron S, Verhoeven J, Vanhoveet C, et al. Recent advancements in F-18-labeled PSMA targeting PET radiopharmaceuticals. Nucl Med Biol. 2022;106:29\u201351.","journal-title":"Nucl Med Biol"},{"key":"1499_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1et M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58:425\u201331.","journal-title":"J Nucl Med"},{"key":"1499_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, et al. Detection efficacy of 18F-PSMA-1007 PET-CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60:362\u20138.","journal-title":"J Nucl Med"},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe SP, Macura KJ, Mena E, et al. PSMA-based 18F-DCFPyL PET-CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411\u20139.","journal-title":"Mol Imaging Biol"},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. PSMA PET-CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET-CT. J Nucl Med. 2018;59:469\u201378.","journal-title":"J Nucl Med"},{"key":"1499_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312.","journal-title":"Eur Urol"},{"key":"1499_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, et al. Proposal for a structured reporting system for prostate-specific membrane antigen\u2013targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018;59:479\u201385.","journal-title":"J Nucl Med"},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s12149-025-02086-9","volume":"39","author":"Y Enei","year":"2025","unstructured":"Enei Y, Yanagisawa T, Okadaet A, et al. Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga\/F-PSMA PET-CT. Ann Nucl Med. 2025;39:1278\u201386.","journal-title":"Ann Nucl Med"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00259-022-05943-1","volume":"50","author":"EG Arnfield","year":"2022","unstructured":"Arnfield EG, Roberts MJ, Pattison DA. Lymph node classification in E-PSMA reporting guidelines for PSMA-PET. Eur J Nucl Med Mol Imaging. 2022;50:8\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2967\/jnumed.118.217588","volume":"59","author":"RA Werner","year":"2018","unstructured":"Werner RA, Bundschuh RA, Bundschuh L, et al. Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET-CT imaging. J Nucl Med. 2018;59:1857\u201364.","journal-title":"J Nucl Med."},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13550-020-0596-4","volume":"10","author":"C Derwael","year":"2020","unstructured":"Derwael C, Lavergne O, Lovinfosseet P, et al. Interobserver agreement of 68Ga-Ga-PSMA-11 PET-CT images interpretation in men with newly diagnosed prostate cancer. EJNMMI Res. 2020;10:15.","journal-title":"EJNMMI Res"},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","volume":"49","author":"DA Pattison","year":"2022","unstructured":"Pattison DA, Debowski M, Gulhane B, et al. Prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68Ga-Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:763\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00259-024-06857-w","volume":"52","author":"SA Esfahani","year":"2024","unstructured":"Esfahani SA, Morris MJ, Sartor O, et al. Standardized template for clinical reporting of PSMA PET\/CT scans. Eur J Nucl Med Mol Imaging. 2024;52:335\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01499-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01499-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:37Z","timestamp":1792516057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01499-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01499-5","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures conducted in this bi-centric study were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Data were collected at Rabin Medical Center as part of a retrospective study protocol approved by the local institutional ethics committee, which waived written informed consent (Reference ID RMC-0242\u201323). For Princess Margaret Cancer Center participants, data were obtained from a prospective Registry Trial (PREP; Institutional Review Board ID: CAPCR #18\u20135656; NCT03718260), with written informed consent obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}